ReproCELL announced that PMDA's face-to-face consultation on the clinical trial plan for iPS-derived neural glial cells (iGRP) had concluded. The date was 26 October 2026, and the company stated that subsequent procedures would be as described in this document.
ReproCELL announced that PMDA's face-to-face consultation on the clinical trial plan using its iPS-derived neural glial cells (iGRP) had concluded. The conclusion of the consultation was announced in an official release, but the main text did not provide specific subsequent procedures or a timetable for progress in clinical development.
The main text only reports the conclusion of the consultation as a fact and does not disclose further details on the plan, schedule or costs. ReproCELL may continue research and development activities involving the same cell type, but its official announcement at this point does not include a plan of subsequent actions.
The article reports the conclusion of PMDA's consultation as a fact and does not specify the current status of clinical development or the timing of future progress. Readers will need to await additional information in the official release and future updates.